References
Mancia G, De Backer G, Dominiczak A, et al.: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007, 28(12):1462–1536.
Hypertension: uncontrolled and conquering the world [editorial]. Lancet 2007, 370(9587):539.
Enseleit F, Luscher TF, Ruschitzka F: Darusentan: a new perspective for treatment of resistant hypertension? Expert Opin Investig Drugs 2008, 17(8):1255–1263.
Schrader J, Tebbe U, Borries M, et al.: [Plasma endothelin in normal probands and patients with nephrologic–rheumatologic and cardiovascular diseases]. Klin Wochenschr 1990, 68(15):774–779.
Saito Y, Nakao K, Mukoyama M, Imura H: Increased plasma endothelin level in patients with essential hypertension. N Engl J Med 1990, 322(3):205.
Krum H, Viskoper RJ, Lacourciere Y, et al.: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998, 338(12):784–790.
Nakov R, Pfarr E, Eberle S: Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens 2002, 15(7 Pt 1):583–589.
Black HR, Bakris GL, Weber MA, et al.: Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 2007, 9(10):760–769.
Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ: The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008, 153(6):1105–1119.
Spieker LE, Mitrovic V, Noll G, et al.: Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators. J Am Coll Cardiol 2000, 35(7):1745–1752.
Luscher TF, Enseleit F, Pacher R, et al.: Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002, 106(21):2666–2672.
Anand I, McMurray J, Cohn JN, et al.: Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004, 364(9431):347–354.
Second pivotal phase III study of Gilead’s darusentan for resistant hypertension misses primary endpoints [press release]. Foster City, CA: Gilead Sciences, Inc; December 14, 2009. Available at http://www.gilead.com/pr_1365747. Accessed December 17, 2009.
Disclosure
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Enseleit, F., Ruschitzka, F. Darusentan in Resistant Hypertension: Lost in Translation. Current Science Inc 12, 1–3 (2010). https://doi.org/10.1007/s11906-009-0081-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11906-009-0081-y